Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R.sup.1, R.sup.2, X.sup.1, X.sup.2, Y.sup.1, and Y.sup.2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

##STR00001##

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R.sup.1, R.sup.2, X.sup.1, X.sup.2, Y.sup.1, and Y.sup.2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

##STR00001##

Disclosed herein, inter alia, are compounds and methods for inhibiting Taspase1 and the treatment of cancer.

Disclosed herein, inter alia, are compounds and methods for inhibiting Taspase1 and the treatment of cancer.

The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.

The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.

A method of treating episodic and chronic nasal congestion of the human nasal passages is disclosed. The present invention combines use of decongestant nasal spray, saline nasal spray, and nasal dilator therapies with minimized risk of incurring rebound congestion. The method may be used as both preventative and withdrawal therapies for patients experiencing rebound congestion. Nasal dilators, decongestant nasal spray and saline nasal spray are provided in kit form whereby users may practice the method.

The present invention provides methods for treating, preventing or ameliorating a fibrotic condition. The methods of the present invention include administering to a patient suffering from a fibrotic condition a therapeutically effective amount an anti-interleukin-36 receptor (anti-IL-36R) antibody.

The present invention provides methods for treating, preventing or ameliorating a fibrotic condition. The methods of the present invention include administering to a patient suffering from a fibrotic condition a therapeutically effective amount an anti-interleukin-36 receptor (anti-IL-36R) antibody.

The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45 Å (Angstroms) or less.